AstraZeneca

News

A single year of adjuvant treatment with AstraZeneca and MSD's PARP inhibitor Lynparza is still providing a survival benefit six years later.

News

After a string of trial failures, MSD claims a partial win for Keytruda and Lynparza in advanced epithelial ovarian cancer.

News

Regeneron's Alnylam-partnered poze-cemdi combination achieves greater disease control measured using LDH than AZ's market-leading Ultomiris.

News

AstraZeneca's Imfinzi becomes the first cancer immunotherapy to be FDA-approved for limited-stage small cell lung cancer (LS-SCLC).

News

Kelun-Biotech has become the second drugmaker to bring a TROP2 ADC to regulatory approval, after its sac-TMT drug was cleared in China

News

Researchers in the UK say that AstraZeneca's benralizumab can have a dramatic impact if it was used to treat acute asthma attacks